8-KRegulation FD

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Mar 5, 2024)

Filed March 5, 2024For Securities:CVS

Summary

CVS Health Corporation (CVS) filed an 8-K on March 5, 2024, primarily to reaffirm its previously issued full-year 2024 financial guidance. The company's senior management team met with investors and participated in a webcast where they reiterated their commitment to achieving at least $7.06 in GAAP diluted Earnings Per Share (EPS) and at least $8.30 in Adjusted EPS for fiscal year 2024. Additionally, CVS Health confirmed its expectation to generate at least $12.0 billion in cash flow from operations for the same period. During the webcast, the Chief Financial Officer provided updates on recent business trends and initiatives. The filing also includes a reconciliation of projected GAAP diluted EPS to projected Adjusted EPS, detailing adjustments for amortization of intangible assets and acquisition-related integration costs associated with the Signify Health and Oak Street Health acquisitions. Investors should note that the company uses non-GAAP measures to provide a clearer view of underlying business performance and trends.

Key Highlights

  • 1Reaffirmation of full-year 2024 GAAP diluted EPS guidance of at least $7.06.
  • 2Reaffirmation of full-year 2024 Adjusted EPS guidance of at least $8.30.
  • 3Reaffirmation of full-year 2024 cash flow from operations guidance of at least $12.0 billion.
  • 4Executive participation in investor meetings and a webcast to discuss business trends and initiatives.
  • 5Disclosure of reconciliation between projected GAAP diluted EPS and projected Adjusted EPS.
  • 6Inclusion of acquisition-related integration costs (Signify Health, Oak Street Health) as a key adjustment in non-GAAP measures.
  • 7Emphasis on non-GAAP measures to enhance comparability of past and current financial performance.

Frequently Asked Questions

The main purpose of this 8-K filing is for CVS Health to reaffirm its previously issued full-year 2024 financial guidance, including GAAP diluted EPS, Adjusted EPS, and cash flow from operations. It also serves to inform investors about management's participation in investor meetings and a webcast where updates on business trends were provided.

CVS Health reaffirmed its full-year 2024 guidance for: GAAP diluted EPS of at least $7.06, Adjusted EPS of at least $8.30, and cash flow from operations of at least $12.0 billion.

The primary adjustments to calculate Adjusted EPS for 2024 include the amortization of intangible assets (estimated at $1.58 per share) and acquisition-related integration costs for Signify Health and Oak Street Health (estimated at $0.18 per share), along with their corresponding tax impacts.

CVS Health provides Adjusted EPS as a non-GAAP financial measure to help investors analyze underlying business performance and trends. The company believes this measure enhances the ability to compare past and current financial performance, excluding certain items that may not reflect ordinary business operations or underlying performance.